Multiple Myeloma 101: Diagnosis, Prognosis, And Risk: Nikhil C. Munshi, Md

Multiple Myeloma 101: Diagnosis, Prognosis, and Risk: Nikhil C. Munshi, MD

Dana-Farber Cancer Institute

Multiple Myeloma 101: Diagnosis, Prognosis, and Risk

Dana-Farber Cancer Institute

Myeloma 101: Diagnosis, Prognosis & Risk | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dr. Munshi on diagnosis and risk assessment in multiple myeloma | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Multiple Myeloma: Diagnosis and Risk Assessment | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

How is multiple myeloma diagnosed and how do risk factors affect treatment? By Dr. Nikhil Munshi

Dana-Farber Cancer Institute

Diagnosis and Risk Assessment In Multiple Myeloma

Dana-Farber Cancer Institute

Dr. Munshi Discusses Multiple Myeloma Treatment Sequencing and Selection

Multiple Myeloma Symposium: Diagnosis and Risk Assessment | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dr. Nikhil Munshi discusses progress in multiple myeloma treatment

Dana-Farber Cancer Institute

2019 Multiple Myeloma Symposium | Diagnosis, Prognosis & Risk

Dana-Farber Cancer Institute

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

CAR T Research and Goals - Nikhil Munshi, MD | MCRT Webcast October 31 (7/10)

HealthTree Foundation for Multiple Myeloma

Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project

Dr. Munshi on Latest Treatment Developments in Multiple Myeloma

CAR-T in multiple myeloma: cilta-cel & ide-cel

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Munshi on the Role of Checkpoint Inhibitors in Myeloma

Nikhil Munshi, MD, on the association between MRD and survival outcomes in multiple myeloma

Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM

Nikhil Munshi, MD, considers how ID2 function impacts oncogenesis in multiple myeloma